Genomics

Biological Dynamics Announces Expanding Adoption of ExoVerita™ Pro Under Early Access Program

Retrieved on: 
Tuesday, April 2, 2024
Research, Infectious Diseases, Genetics, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Exosome, EV, Plasma, ACE, Serum, Patient, RNA, DNA, Cancer, Personalized medicine, MD, Fluid mechanics, Doctor of Philosophy, AACR, Genomics, Prognosis, Biology, Centrifuge, Pharmaceutical industry

Biological Dynamics, Inc. , a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.
  • ExoVerita Pro supports exosome-based research efforts, helping to accelerate early disease detection, determine therapeutic response, and more.
  • “Research has shown that exosomes carry important information about human health, but studying them has proven challenging,” said Paul R. Billings, MD, Ph.D., CEO and Chairman of Biological Dynamics.
  • Biological Dynamics will showcase ExoVerita Pro in Booth #4340 at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, Calif., April 5-10.

Watchmaker Genomics Announces Launch of Cost-effective RNase Inhibitor for Single-cell, Single-nuclei, and Pathogen Detection Applications

Retrieved on: 
Tuesday, April 2, 2024
Medical Supplies, Medical Devices, Health, Genetics, Other Health, Biotechnology, Watchmaker, Marketing, Ribonuclease, RNA, Genomics, Pharmaceutical industry

Watchmaker Genomics, a provider of innovative solutions for molecular analysis, announced the launch of a high-purity RNase Inhibitor that is well-suited for a wide range of applications where maintaining RNA integrity is critical, including single-cell and single-nuclei sequencing, as well as pathogen detection.

Key Points: 
  • Watchmaker Genomics, a provider of innovative solutions for molecular analysis, announced the launch of a high-purity RNase Inhibitor that is well-suited for a wide range of applications where maintaining RNA integrity is critical, including single-cell and single-nuclei sequencing, as well as pathogen detection.
  • “We are pleased to bring our RNase Inhibitor to market,” said Sandra Rowe, Vice President of Marketing at Watchmaker.
  • “We aim to be a partner for our customers and provide high-performing yet cost-effective solutions to allow for higher throughput and increased sensitivity.”
    Key features of Watchmaker’s RNase Inhibitor include:
    The launch of the RNase Inhibitor complements Watchmaker’s Precision Enzymes portfolio, which includes the highly thermostable and inhibitor-tolerant StellarScript HT+ Reverse Transcriptase designed for sensitive pathogen detection assays.

Mosaic Biosciences Expands Its Leading Drug Discovery and Development Expertise

Retrieved on: 
Tuesday, April 2, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biogen, Obesity, Drug discovery, Cancer immunotherapy, Diabetes, Malavi, History, BMS, Doctor of Philosophy, Bristol Myers Squibb, CTI, Therapy, Genomics, NASH, GNF, CSO, Antibody, Inflation, Autoimmunity, DSM-IV codes, Pharmaceutical industry

Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.

Key Points: 
  • Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.
  • Both recognized leaders join the company as it grows to meet increased demand for its comprehensive and integrated drug discovery research services.
  • “I am excited to leverage my drug discovery and clinical development expertise to further position Mosaic Biosciences as the partner of choice for discovering innovative protein therapeutics in a disease agnostic manner,” said Malavi.
  • “Mosaic Biosciences has a strong history of technical innovations and partner support that makes it a leader in the discovery of successful next-generation protein therapeutics,” said Scott.

Global Proteomic Biomarker Analytics Market Analysis Report 2024 with Executive & Consultant Guides; Including Customized Forecasting and Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Health, Biotechnology, Illumina, Assay, Place, Proteomics, Genomics, Research, Cancer, Application

The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Where genomics couldn't find all the answers proteomics is stepping up to the plate.
  • Proteomic Biomarker Analytics is just finding its feet, but the opportunity is to understand the front line players, the actual proteins and protein complexes, that do the work of managing cellular life.
  • The report forecasts the market size out for five years for a number of different market segments.

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Genetics, Health Technology, Oncology, Genomics, Cancer, Conference, PSNL

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.

Key Points: 

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.

BioSkryb Genomics to Present Novel Research on Tumor Heterogeneity at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Disease, Transcriptome, Malignancy, Neoplasm, DNA, Genome, Workflow, AACR, Doctor of Philosophy, Phenotype, Genomics, SNV, Ageing, CNV, Mobile phone

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.
  • “Tumor heterogeneity is a key challenge for researchers in the cancer research field.
  • As tumors evolve, subclones emerge with mutations that convey adaptive phenotypes, including resistance to therapies,” said Suresh Pisharody, CEO of BioSkryb.
  • “Our next generation single-cell technology gives scientists the tools to better understand the way tumors evolve with a comprehensive, scalable, and streamlined workflow.

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Genomics, PSNL, Immunotherapy, Patient, NeXT, Abstract, AACR, MRD, Melanoma, Neoplasm, Medical imaging

“Personalis is excited to present data showing our ultra-sensitive MRD test, NeXT Personal, has the potential to find recurrent cancer earlier and monitor response in late-stage cancer patients receiving immunotherapy,” said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

Key Points: 
  • “Personalis is excited to present data showing our ultra-sensitive MRD test, NeXT Personal, has the potential to find recurrent cancer earlier and monitor response in late-stage cancer patients receiving immunotherapy,” said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.
  • Personalis will be sharing progress with collaborative research findings as well as the latest clinical results related to NeXT Personal.
  • Changes in ctDNA levels detected with NeXT Personal predicted therapy response and overall survival in late-stage hepatocellular carcinoma patients treated with a personalized cancer vaccine.
  • Analytical validation of NeXT Personal demonstrated ultra-sensitivity down to 1 PPM of ctDNA and high specificity, reinforcing the potential to detect recurrent cancer earlier.

7th Annual Digi-Tech Pharma & AI Conference: Registration Now Open - London, United Kingdom - May 28-29, 2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Health Technology, Pharmaceutical, Health, Genomics, Informatics, GMS, Conference, Data science, Medication, Clinical, Drug discovery, Intelligence, Partnership, Internet of things, Blockchain, Value, Artificial intelligence, Science, AI, Digital health, Deep learning, Medicine, Pleasure, Cloud computing, Head, Machine learning, Data management, VPS, Virtual reality, Fine chemical

The "Digi-Tech Pharma & AI 2024" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Digi-Tech Pharma & AI 2024" conference has been added to ResearchAndMarkets.com's offering.
  • The 7th Annual Digi-Tech Pharma & AI conference, a premier Pharmaceutical Technology Conference, brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare industry.
  • Meet the decision makers, benchmark and learn from real-life use cases to drive organizational change and to understand the new cutting-edge technologies and practical solutions.
  • It gives us a great pleasure in welcoming you to our whole new pharmaceutical technology conference 7th Annual Digi-Tech Pharma & AI 2024.

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Genetics, Health, Oncology, WGS, Genomics, Plasma, Congress, PPM, PSNL, NSCLC, Adenocarcinoma, Patient, Publishing, DNA, Cancer, LUAD, Lung cancer, NeXT, Neoplasm, ESMO, MRD, Medicare, Recurrence, Medical imaging

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.
  • “The robust validation results in this publication provide a foundational building block towards achieving Medicare coverage for NeXT Personal,” said Richard Chen, MD, MS, Chief Medical Officer and Executive Vice President, R&D of Personalis.
  • “Taken together, the results show NeXT Personal’s capability for ultra-sensitive detection of ctDNA in patient plasma samples and the test’s potential to reliably inform clinicians and patients on residual cancer, cancer treatment response, and cancer recurrence through ctDNA detection, earlier than conventional detection approaches,” Chen noted.
  • This data from the TRACERx Study demonstrated the assay was able to find cancer nearly a year ahead of imaging and was predictive of clinical outcomes in early-stage lung cancer patients.

Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration

Retrieved on: 
Tuesday, March 26, 2024
Research, Legal, Medical Devices, Patent Law, Genetics, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Trade, CVC, Patent, RNA, CNIPA, Emmanuelle, University, Genomics, CRISPR, Eukaryote, Intellectual property, Cas9

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.

Key Points: 
  • ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.
  • The decision to uphold the patent right in China follows a recent decision by the Japanese Patent Office earlier this year to uphold JP6692856, also part of the CVC portfolio1.
  • The decision by the CNIPA, fully upholding the patent, further demonstrates its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology.
  • Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: “The decision by the CNIPA is testament to the strength of the foundational CVC CRISPR/Cas9 patent portfolio.